Centrient* appoints Faye Freeman as Chief Executive Officer
Rex Clements steps down after six years and will support a smooth transition in an advisory capacity
Rotterdam March 11 — Centrient, a global leader in sustainable, enzymatic antibiotics*, next-generation statins, and anti-fungals, today announced the appointment of Faye Freeman as Chief Executive Officer, effective immediately, following a planned leadership transition.
Faye brings more than 20 years of experience across global regulated manufacturing environments, most recently serving as CEO of Aurorium, a specialty ingredients and materials manufacturer. She is recognised for her commitment to operational excellence, building high‑performing teams, and embedding a strong culture of customer centricity.
Throughout her career, Faye has championed approaches that not only meet customer needs but genuinely delight them, strengthening long‑term partnerships and driving sustainable business growth. Her leadership philosophy and deep alignment with Centrient’s purpose position her well to lead the organisation into its next phase.
Rex is stepping down after six years leading the company and will remain closely involved over the coming months to support the transition and advise Faye and the board. Reflecting on his tenure, Mr. Clements shared: “After six years, this is a natural time for this transition. I am proud of how Centrient has evolved into a strong, standalone company that is a leader in antibiotics and provides over 1.5 billion treatments around the world annually. Centrient has an essential role in healthcare and a strong future ahead.”
Speaking about her appointment, Ms. Freeman commented: “Centrient’s role in advancing global health by reliably supplying essential medicines around the world deeply resonates with me. The company’s dedication to delivering excellence in everything it does, and to delighting its customers, reflects values I strongly believe in. I am honoured to step into the role of Chief Executive Officer and am grateful to Rex for his commitment over the past six years, as well as for his support during this transition. I am excited to work alongside this talented team as we shape the next chapter of Centrient’s success.”
Ms. Freeman will lead Centrient as it navigates a changing global landscape, with a focus on executing strategy, serving customers, and supporting teams across the business.
---------------------------------------------------------------------------------------------------------------------
About Centrient Pharmaceuticals
Centrient Pharmaceuticals is the global business-to-business leader in sustainable, enzymatic antibiotics, next-generation statins, and anti-fungals. We are a pharmaceutical company with a clear Purpose: to improve lives through innovative and sustainable manufacturing of medicines - saving the lives of millions of people around the world annually. Regarding our portfolio, we produce and sell intermediates and active pharmaceutical ingredients (APIs), as well as finished dosage forms (FDFs). Centrient Pharmaceuticals is a Board Member of the AMR Industry Alliance and a long-time advocate for industry responsibility in manufacturing.
For more information, please visit www.centrient.com, www.linkedin.com/company/centrient or contact Centrient Pharmaceuticals Global Communications and Public Affairs Director, Neil Moorhouse. E-Mail: neil.moorhouse@centrient.com.
*( 1) “Centrient Pharmaceuticals”, “Centrient” in this content are sometimes used for convenience where references are made to Centrient International Pharmaceuticals B.V, and or one or more of its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to Centrient Pharmaceuticals International B.V. and or one or more of its subsidiaries in general or to those who work for them. These terms are also used where no useful purpose is served by identifying the particular entity or entities. “Subsidiaries”, “Centrient subsidiaries” and “Centrient companies” as used in this content refer to entities over which Centrient Pharmaceuticals International B.V. either directly or indirectly has control. The term “Centrient interest” is used for convenience to indicate the direct and/or indirect ownership interest held by Centrient Pharmaceuticals International B.V. in an entity or unincorporated joint arrangement, after exclusion of all third-party interest.